Enhancement of the efficacy of mitomycin c-mediated apoptosis in human colon cancer cells with RNAi‑based thioredoxin reductase 1 deficiency

Koedrith,Preeyaporn; Seo,Young Rok

doi:10.3892/etm.2011.304

Enhancement of the efficacy of mitomycin c-mediated apoptosis in human colon cancer cells with RNAi‑based thioredoxin reductase 1 deficiency

Authors:
- Preeyaporn Koedrith
- Young Rok Seo
View Affiliations

Affiliations: Department of Life Science, Dongguk University-Seoul, Seoul 100-715, Republic of Korea
Published online on: June 30, 2011 https://doi.org/10.3892/etm.2011.304
Pages: 873-878

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thioredoxin reductase 1 (Trr1) is an antioxidant and redox regulator that functions in governing the cellular redox state and survival against oxidative insults in mammals. However, this selenoprotein is also overexpressed in various forms of malignant cancers, leading to the hypothesis that Trr1 may be a potential target for cancer therapy. A quinone anticancer drug, mitomycin C (MMC), has been clinically used in the treatment of several types of tumors, including those of the colon. MMC exerts its activity via ROS induction and further results in DNA cross-linkage. To evaluate the significant role of Trr1 in MMC resistance in human colon cancer (RKO) cells, specific reduction in the expression of Trr1 was achieved using short-hairpin RNA (shRNA)-based interference. Our results showed that stable Trr1 shRNA knockdown manifested higher cellular susceptibility to MMC in comparison to that in wild-type cells. In addition, increased intracellular ROS accumulation appeared in the Trr1 shRNA knockdown cells compared to the RKO wild-type cells, in proportion to a relatively higher fraction of the DNA damage reporter protein phosphorylated histone ‘γ-H2AX’. Notably, a neutral comet assay demonstrated that DNA double-strand breaks were highly induced in the Trr1-deficient cancer cells in the presence of MMC, presumably stimulating cancer cell death. Our results also revealed that MMC-induced apoptosis was associated with enhancement of oxidative damage to DNA. These results suggest that the specific knockdown of Trr1 expression via shRNA vector interference technology may be a potent molecular strategy by which to enhance the effectiveness of MMC-mediated killing in human colon cancer cells, through acceleration of double-strand DNA damage-oxidative stress as a trigger for apoptosis. This implies that Trr1 may be a prime target for enhancing the effectiveness of MMC chemotherapy in combination with specific RNA interference.

View Figures

View References

1.	Sartorelli AC: The role of mitomycin antibiotics in the chemotherapy of solid tumors. Biochem Pharmacol. 35:67–69. 1986. View Article : Google Scholar : PubMed/NCBI
2.	Crooke ST and Bradner WT: Mitomycin C: a review. Cancer Treat Rev. 3:121–139. 1976. View Article : Google Scholar
3.	Sartorelli AC, Hodnick WF, Belcourt MF, Tomasz M, Haffty B, Fischer JJ and Rockwell S: Mitomycin C: a prototype bioreductive agent. Oncol Res. 6:501–508. 1994.PubMed/NCBI
4.	Tomasz M and Palom Y: The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther. 76:73–87. 1997. View Article : Google Scholar
5.	Verweij J and Stoter G: Severe side effects of the cytotoxic drug mitomycin-C. Neth J Med. 30:43–50. 1987.PubMed/NCBI
6.	Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R and Gladyshev VN: Characterization of mammalian selenoproteins. Science. 300:1439–1443. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Arnér ES and Holmgren A: Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 267:6102–6109. 2000.
8.	Arnér ES and Holmgren A: The thioredoxin system in cancer. Semin Cancer Biol. 16:420–426. 2006.
9.	Choi JH, Kim TN, Kim S, Baek SH, Kim JH, Lee SR and Kim JR: Over-expression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res. 22:3331–3335. 2002.PubMed/NCBI
10.	Rundlöf AK and Arnér ES: Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling event. Antioxid Redox Signal. 6:41–52. 2004.PubMed/NCBI
11.	Pan SS, Forrest GL, Akman SA and Hu LT: NAD(P)H: quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells. Cancer Res. 55:330–335. 1995.PubMed/NCBI
12.	Perry RR, Greaves BR and Kang Y: Development and initial characterization of a mitomycin C-resistant colon cancer cell line variant. Cancer Chemother Pharmacol. 32:326–328. 1993. View Article : Google Scholar : PubMed/NCBI
13.	Willson JKV, Long BH, Marks ME, Brattain DE, Wiley JE and Brattain MG: Mitomycin C resistance in a human colon carcinoma cell line associated with cell surface protein alterations. Cancer Res. 44:5880–5885. 1984.PubMed/NCBI
14.	Biaglow JE and Miller RA: The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther. 4:6–13. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Fujino G, Noguchi T, Takeda K and Ichijo H: Thioredoxin and protein kinases in redox signaling. Semin Cancer Biol. 16:427–435. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Yoo MH, Xu XM, Carlson BA, Patterson AD, Gladyshev VN and Hatfield DL: Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem. 281:13005–13008. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Yoo MH, Xu XM, Carlson BA, Patterson AD, Gladyshev VN and Hatfield DL: Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS One. 2:e11122007. View Article : Google Scholar : PubMed/NCBI
18.	Hatfield DL, Yoo MH, Carlson BA and Gladyshev VN: Selenoproteins that function in cancer prevention and promotion. Biochim Biophys Acta. 1790:1541–1545. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Taneja N, Davis M, Choy JS, Beckett MA, Singh R, Kron SJ and Weichselbaum RR: Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem. 279:2273–2280. 2004. View Article : Google Scholar : PubMed/NCBI
20.	Fairbairn DW and O'Neill KL: The neutral comet assay is sufficient to identify an apoptotic ‘window’ by visual inspection. Apoptosis. 1:91–94. 1996.
21.	Wojewodzka M, Buraczewska I and Kruszewski M: A modified neutral comet assay: elimination of lysis at high temperature and validation of the assay with anti-single-stranded DNA antibody. Mutat Res. 518:9–20. 2002. View Article : Google Scholar : PubMed/NCBI
22.	Bachur NR, Gordon SL and Gee MV: A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res. 38:1745–1750. 1978.PubMed/NCBI
23.	Handa K and Sato S: Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation. Gann. 66:43–47. 1975.
24.	Brendel M and Ruhland A: Relationships between functionality and genetic toxicology of selected DNA-damaging agents. Mutat Res. 133:51–85. 1984. View Article : Google Scholar : PubMed/NCBI
25.	Lawley PD and Phillips DH: DNA adducts from chemotherapeutic agents. Mutat Res. 355:13–40. 1996. View Article : Google Scholar : PubMed/NCBI
26.	Adikesavan AK and Jaiswal AK: Thioredoxin-like domains requied for glucose regulatory protein 58-mediated reductive activation of mitomycin C leading to DNA cross-linking. Mol Cancer Ther. 6:2719–2727. 2007. View Article : Google Scholar : PubMed/NCBI
27.	Kennedy KA, McGurl JD, Leondaridis L and Alabaster O: pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells. Cancer Res. 45:3541–3547. 1985.PubMed/NCBI
28.	Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J and Powis G: Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 16:3459–3466. 1996.PubMed/NCBI
29.	Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L and Arnér ES: High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic Biol Med. 47:1661–1671. 2009. View Article : Google Scholar : PubMed/NCBI
30.	Jeggo PA and Löbrich M: DNA double-strand breaks: their cellular and clinical impact? Oncogene. 26:7717–7719. 2007. View Article : Google Scholar : PubMed/NCBI